Loading patent…
AssigneeThe General Hospital Corporation
InventorsKhalid Shah, Kaoru Tamura, Hiroaki Wakimoto
Estimating the term…
Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV. One form of TRAIL contained within the oncolytic virus is a secreted form of TRAIL. Examples of various forms of oHSV and secreted TRAIL are disclosed therein. Also disclosed are host cells and therapeutic formulations comprising the recombinant oncolytic virus. Also disclosed are methods of treating cancer in a subject by administering a therapeutic formulation comprising the recombinant oncolytic virus to the subject.
A method of inhibiting tumor progression in a subject comprising contacting the tumor with an effective amount of a pharmaceutical composition comprising a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or a biologically active fragment thereof, in expressible form.
A method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition comprising a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or a biologically active fragment thereof, in expressible form, to thereby treat the cancer.
Dependencies are inferred from the claim text.